Overview of Dantonic ™

Abstract

In 2004, the market share of Dantonic ™ in Chinese patent medicines for the treatment of coronary heart disease was 35.59 % (Fig. 9.1). The development and production of Dantonic ™ began with the adaptation of good agricultural practices (GAP) in the planting and harvesting of Danshen, notoginseng , and Cinnamomum camphora (containing borneol ). At the same time, Dr. Yan Xijun, the inventor of Dantonic ™, proposed for the first time in the world the concept of good extracting practice (GEP ) and its detailed operating procedures. The concept and procedures have standardized the key links in the production of TCM or herbal medicinal products and ensured that the contents of the components of the TCM or herbal medicinal products will not be affected by factors like weather and geographic locations, and thus guaranteed their quality. The standardized extracts attained through GEP are manufactured according to GMP into the finished products and fully comply with the pharmaceutical regulatory requirements. Meanwhile, the current internationally accepted standard GSP requirements are also adopted in the marketing practice, with a set of strict drug sales and supervision systems, so that the safety of the patients and the effectiveness of the drugs are ensured to the greatest extent.